GlaxoSmithKline Pharmaceuticals Limited delivers strong financials led by Pharma growth
GlaxoSmithKline Pharmaceuticals Ltd today declared its financial results for the quarter ended December 31, 2021. Revenue for the quarter from Continuing Operations came in at Rs 808 crores recording a growth of 2%. PBT (before exceptional items) from Continuing Operations for the quarter at Rs 189 crores recorded a growth of 6%. EBITDA from Continuing Operations at Rs 197 crores recorded a growth of 8%.
Revenue from Continuing Operations for the nine months ended December 31, 2021 was Rs 2426 crores recording a growth of 11%. PBT (before exceptional items) from Continuing Operations for the nine months at Rs 585 crores recorded a growth of 27%. EBITDA from Continuing Operations at Rs 582 crores recorded a growth of 31%.
Commenting on the results, Sridhar Venkatesh, Managing Director, GlaxoSmithKline Pharmaceuticals Limited, said, "GSK's established pharma portfolio recorded strong double-digit growth, driven by our core legacy brands such as Ca1pol, Augmentin and Ceftum.
While our promoted brands grew, our vaccines business was impacted on account of the third wave of the pandemic. However, as this phase of the pandemic recedes and schools open up across the country, we are witnessing a steady uptake in vaccination. We also continue to invest in our brands and raise awareness amongst parents about more innovative vaccines from our portfolio.
During the quarter, we concluded the sale of the Vemgal plant in Karnataka. In the subsequent quarters, we will also aim to close the transfer of lodex and Ostocalcium brands to GlaxoSmithKline Asia Private Limited, as part of GSK plc's plans to create two world class companies in pharmaceuticals and consumer healthcare."
About GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of GlaxoSmithKline plc, one of the world's leading research-
based pharmaceutical and healthcare companies, committed to improving the quality of human life by enabling
people to do more, feel better and live longer. For more information, visit www.gsk-india.com
Media Contact
Ransom D'Souza
Communications and Government Affairs
Email: ransom.a.dsouza©gsk.com
